Showing results (221-230 of 258) with videos related to
Sort By:
Pageof 26
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 15, 2025
Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults with HIV-1: ACTG A5357Babafemi O Taiwo, Yu Zheng, Katherine Rodriguez, et al.Journal of Synchrotron Radiation|September 2, 2014
A novel high-temperature furnace for combined in situ synchrotron X-ray diffraction and infrared thermal imaging to investigate the effects of thermal gradients upon the structure of ceramic materialsJames B Robinson, Leon D Brown, Rhodri Jervis, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 19, 2017
ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mLBabafemi O Taiwo, Lu Zheng, Andrei Stefanescu, et al.AIDS (London, England)|June 10, 2016
Differential CD4+ cell count increase and CD4+ : CD8+ ratio normalization with maraviroc compared with tenofovirEllen S Chan, Alan L Landay, Todd T Brown, et al.Antimicrobial Agents and Chemotherapy|September 23, 2015
Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral TherapySunil Parikh, Fatai Fehintola, Liusheng Huang, et al.Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|September 10, 2016
Quantifying Bulk Electrode Strain and Material Displacement within Lithium Batteries via High-Speed Operando Tomography and Digital Volume CorrelationDonal P Finegan, Erika Tudisco, Mario Scheel, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 3, 2018
Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized TrialBabafemi O Taiwo, Vincent C Marconi, Baiba Berzins, et al.Journal of Medicinal Chemistry|January 20, 2000
Design, synthesis, and biological evaluation of matrix metalloproteinase inhibitors derived from a modified proline scaffoldM Cheng, B De, N G Almstead, et al.Journal of Medicinal Chemistry|January 15, 1999
Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinasesS Pikul, K L McDow Dunham, N G Almstead, et al.Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|April 14, 2006
Comparison of the pharmacology of hydroxamate- and carboxylate-based matrix metalloproteinase inhibitors (MMPIs) for the treatment of osteoarthritisM J Janusz, E B Hookfin, K K Brown, et al.Pageof 26